drugset / Trial / NCT00944554

Relapse Prevention With Varenicline

NCT00944554

Phase 4 Completed 104 enrolled Johns Hopkins University Pfizer · collab
RandomizedParallel-groupTriple-blindDiagnostic

Summary

This study aims to determine if varenicline (Chantix®), currently used as a smoking cessation aid, will decrease the likelihood of relapse to smoking following a programmed lapse in the laboratory. The hypothesis is that varenicline will reduce the reinforcing effects of smoking and will delay or prevent relapse compared to placebo.

Timeline

Start
2008-10
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Varenicline Small molecule